These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1060 related articles for article (PubMed ID: 29482595)

  • 1. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.
    Li X; Shao C; Shi Y; Han W
    J Hematol Oncol; 2018 Feb; 11(1):31. PubMed ID: 29482595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
    Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
    Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
    Gao A; Sun Y; Peng G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Opportunities and Challenges in Cancer Immunotherapy.
    Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
    Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.
    Chuang YC; Tseng JC; Huang LR; Huang CM; Huang CF; Chuang TH
    Front Immunol; 2020; 11():1075. PubMed ID: 32547560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of novel immunotherapy targeting cancer immune evasion].
    Tamada K
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1062-5. PubMed ID: 25248888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting innate sensing in the tumor microenvironment to improve immunotherapy.
    Liu Z; Han C; Fu YX
    Cell Mol Immunol; 2020 Jan; 17(1):13-26. PubMed ID: 31844141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.
    Shi T; Ma Y; Yu L; Jiang J; Shen S; Hou Y; Wang T
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29735917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
    Ginefra P; Lorusso G; Vannini N
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
    Fares CM; Van Allen EM; Drake CG; Allison JP; Hu-Lieskovan S
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():147-164. PubMed ID: 31099674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
    Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
    Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery Strategies for Immune Checkpoint Blockade.
    Chen Q; Wang C; Chen G; Hu Q; Gu Z
    Adv Healthc Mater; 2018 Oct; 7(20):e1800424. PubMed ID: 29978565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
    Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
    Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
    Ungefroren H
    Expert Opin Ther Targets; 2019 Aug; 23(8):679-693. PubMed ID: 31232607
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer.
    Shevchenko I; Bazhin AV
    Front Immunol; 2018; 9():1816. PubMed ID: 30131808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.